ISIS Pharmaceuticals, Inc.  

(Public, NASDAQ:ISIS)   Watch this stock  
Find more results for ISIS
42.28
+0.40 (0.96%)
Sep 19 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 41.45 - 42.66
52 week 22.25 - 62.66
Open 41.96
Vol / Avg. 3.14M/2.18M
Mkt cap 4.98B
P/E     -
Div/yield     -
EPS -0.79
Shares 117.74M
Beta 1.42
Inst. own 89%
Nov 3, 2014
Q3 2014 Isis Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Oct 1, 2014
Isis Pharmaceuticals Inc at Leerink Rare Disease Roundtable - 8:00AM EDT - Add to calendar
Sep 8, 2014
Isis Pharmaceuticals Inc at Morgan Stanley Healthcare Conference
Sep 3, 2014
Isis Pharmaceuticals Inc at Citi Biotech Conference
Aug 4, 2014
Q2 2014 Isis Pharmaceuticals Inc Earnings Call
Aug 4, 2014
Q2 2014 Isis Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin -21.17% -41.17%
Operating margin -11.65% -35.08%
EBITD margin - -28.44%
Return on average assets -5.87% -8.71%
Return on average equity -13.08% -21.61%
Employees 304 -
CDP Score - -

Address

2855 Gazelle Court
CARLSBAD, CA 92010
United States - Map
+1-760-9319200 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Isis Pharmaceuticals, Inc. develops therapeutic drugs inhibiting cell protein synthesis. The Company's principal activity is to develop and market RNA(RiboNucleicAcid)-based novel drugs to treat important diseases such as cardiovascular diseases, diabetes and asthma

Officers and directors

Stanley T. Crooke M.D., Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 69
Bio & Compensation  - Reuters
Elizabeth L. Hougen Chief Financial Officer, Senior Vice President - Finance
Age: 52
Bio & Compensation  - Reuters
B. Lynne Parshall J.D. Chief Operating Officer, Corporate Secretary, Director
Age: 59
Bio & Compensation  - Reuters
Patrick R. O'Neil Esq. Senior Vice President - Legal, General Counsel
Age: 40
Bio & Compensation  - Reuters
C. Frank Bennett Ph.D. Senior Vice President - Antisense Research
Age: 57
Bio & Compensation  - Reuters
Richard S. Geary Ph.D. Senior Vice President - Development
Age: 56
Bio & Compensation  - Reuters
Brett P. Monia Ph.D. Senior Vice President - Drug Discovery and Corporate Development
Age: 52
Bio & Compensation  - Reuters
Joseph Loscalzo M.D., Ph.D. Director
Age: 62
Bio & Compensation  - Reuters
Spencer R. Berthelsen M.D. Independent Director
Age: 62
Bio & Compensation  - Reuters
Breaux B. Castleman Independent Director
Age: 73
Bio & Compensation  - Reuters